ADMA Biologics (ADMA) Q4 2024 earnings summary

Executive summary

• FY 2024 revenue reached $426.5 million, up 65% year-over-year, driven by strong Asceniv demand and expanded plasma supply contracts.

• Adjusted EBITDA for 2024 was $164.6 million, up 309% year-over-year; GAAP net income was $197.7 million, including an $84.3 million valuation allowance tax benefit.

• Adjusted net income for 2024 was $119.2 million, a dramatic increase from $0.7 million in 2023.

• Year-end cash exceeded $103 million, with $60 million in debt discharged in 2H 2024, resulting in a net cash surplus over $75 million in debt.

• Long-term high-titer plasma supply contracts and anticipated FDA approval of a yield enhancement process are expected to support durable growth and potential to exceed $1 billion in annual revenue before 2030.

Financial highlights

• Q4 2024 revenue was $117.5 million, up 59% from Q4 2023; full-year 2024 revenue was $426.5 million, up 65% from 2023.

• Gross profit for 2024 was $219.6 million, with gross margin improving to 51.5% from 34.4% in 2023, driven by higher-margin IG sales and operational efficiencies.

• Adjusted EBITDA for 2024 was $164.6 million, up from $40.2 million in 2023; Q4 adjusted EBITDA was $48.3 million.

• Adjusted net income for 2024 was $119.2 million, compared to $0.7 million in 2023.

• Working capital at year-end was $275.9 million, with $170.2 million in inventory and $103.1 million in cash.

Outlook and guidance

• 2025 and 2026 revenue guidance raised to over $490 million and $605 million, with adjusted EBITDA guidance increased to over $225 million and $305 million, respectively.

• Adjusted net income guidance for 2025 and 2026 raised to more than $175 million and $235 million.

• Yield enhancement process, if approved mid-2025, could provide 20% more IG output and upside to current guidance.

• Total annual revenue expected to exceed $1 billion prior to 2030, with outsized earnings growth anticipated.

• Asceniv's market opportunity projected to be $1 billion+ annually, with robust IP protection through at least 2035.